Source: Eur Respir J 2007; 29: 229-230



Rating:

Share or cite this content

Citations should be made in the following way:
Brennan S.. Revisiting α1-antitrypsin therapy in cystic fibrosis: can it still offer promise?. Eur Respir J 2007; 29: 229-230

Member's Comments

No comment yet.

Related content which might interest you: Genomically-guided therapies: a new era for cystic fibrosis Source: Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases Year: 2020 What’s new in cystic fibrosis? Source: International Congress 2018 – Paediatric Year in Review Year: 2018 Update on new treatments for cystic fibrosis Source: Virtual Congress 2020 – Updates in cystic fibrosis Year: 2020 Cystic fibrosis: prospects for therapy of some class 1 mutations Source: Annual Congress 2007 - Cystic fibrosis: will the new biology deliver? Year: 2007 Novel therapeutics for cystic fibrosis Source: ERS Webinar 2020: Novel therapeutics for cystic fibrosis Year: 2020 Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard Source: Eur Respir J 2015; 45: 1208-1210 Year: 2015 Health-economic aspects of cystic fibrosis screening and therapy Source: Eur Respir Monogr 2014; 64: 304-319 Year: 2014 Lung inflammation in cystic fibrosis: an overlooked therapeutic target? Source: Virtual Congress 2020 – Cystic fibrosis: from cradle to old age Year: 2020 Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy Source: Breathe, 17 (4) 210112; 10.1183/20734735.0112-2021 Year: 2021 Trying to find a cure for cystic fibrosis: CFTR biomarkers as outcomes Source: Eur Respir J 2013; 42: 1156-1157 Year: 2013 Trying to find a cure for cystic fibrosis: CFTR biomarkers as outcomes Source: Eur Respir J 2013; 42: 1155 Year: 2013 Personalised medicine for cystic fibrosis: treating the basic defect Source: Eur Respir Rev 2013; 22: 3-5 Year: 2013 Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis Source: Eur Respir J, 51 (6) 1702457; 10.1183/13993003.02457-2017 Year: 2018 The need for lung transplantation in cystic fibrosis (CF) in the era of new treatment Source: Virtual Congress 2020 – Lung transplantation in the era of new drugs Year: 2020 Idiopathic pulmonary fibrosis: present understanding and future options Source: Eur Respir Rev 2011; 20: 132-133 Year: 2011 Tezacaftor-ivacaftor for the treatment of cystic fibrosis: what’s next? Source: International Congress 2018 – Therapeutic breakthroughs Year in Review Year: 2018 Late Breaking Abstract: Denufosol: A novel ion channel regulator and investigational early-intervention therapy for cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease and much more Year: 2010